Breaking News Instant updates and real-time market news.

UBER

Uber

$39.76

-0.155 (-0.39%)

, IOVA

Iovance Biotherapeutics

$17.83

0.7 (4.09%)

09:02
05/31/19
05/31
09:02
05/31/19
09:02

Fly Intel: Pre-market Movers

HIGHER: Iovance Biotherapeutics (IOVA), up 6% after announcing updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma. UP AFTER EARNINGS: Uber (UBER), up 2%... Big Lots (BIG), up 11%... Genesco (GCO), up 10%... Williams-Sonoma (WSM), up 12%. DOWN AFTER EARNINGS: Nutanix (NTNX), down 18%... Zuora (ZUO), down 34%... Gap (GPS), down 14%. LOWER: PG&E (PCG), down 2% after Bloomberg reported a group of PG&E creditors could preempt the company's efforts to exit bankruptcy by presenting a restructuring plan that could be worth at least $45B.

UBER

Uber

$39.76

-0.155 (-0.39%)

IOVA

Iovance Biotherapeutics

$17.83

0.7 (4.09%)

BIG

Big Lots

$26.01

-0.42 (-1.59%)

GCO

Genesco

$40.25

-0.49 (-1.20%)

WSM

Williams-Sonoma

$51.69

0.53 (1.04%)

NTNX

Nutanix

$32.68

-1.02 (-3.03%)

ZUO

Zuora

$19.87

-0.46 (-2.26%)

GPS

Gap

$20.60

-0.23 (-1.10%)

PCG

PG&E

$17.78

0.64 (3.73%)

  • 31

    May

  • 31

    May

  • 31

    May

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 18

    Jun

  • 19

    Jun

  • 21

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

UBER Uber
$39.76

-0.155 (-0.39%)

05/31/19
DADA
05/31/19
NO CHANGE
Target $46
DADA
Neutral
Uber price target lowered to $46 from $53 at DA Davidson
DA Davidson analyst Tom White lowered his price target on Uber (UBER) to $46 and kept his Neutral rating after its Q1 results revealed "few surprises". The analyst notes that although the management was more positive on moderating competition, as Uber and Lyft (LYFT) start to compete "more around brand and product" rather than price, he does not expect major changes in the buy-side estimates on the stock. White notes that his new price target assumes a "more conservative" 4.1-time multiple on enterprise value relative to his expected FY20 sales.
05/31/19
ATLE
05/31/19
UPGRADE
Target $52
ATLE
Overweight
Atlantic upgrades Uber on 'increasingly benign' competitive environment
Atlantic Equities analyst James Cordwell upgraded Uber Technologies to Overweight from Neutral while lowering his price target for the shares to $52 from $55. The stock closed yesterday down 14c to $39.80. The ridehailing competitive environment is becoming "increasingly benign" while Uber shares have become more attractively valued, Cordwell tells investors in a research note. The analyst expects a better competitive environment to drive accelerating revenue growth and moderating segment losses across fiscal 2019. Further, a new Uber Eats fee structure should augment the company's food delivery economics while enabling "rapid" bookings growth, Cordwell tells investors in a research note.
05/31/19
JPMS
05/31/19
NO CHANGE
Target $86
JPMS
Overweight
JPMorgan says buy Lyft as shares offer 50% potential upside
After hosting investor meetings with management, JPMorgan analyst Doug Anmuth recommends buying shares of Lyft (LYFT) on the "increasingly rational" ridesharing industry as well as the company's improving profitability. Management's overall tone was very confident around the easing of the competitive environment in U.S. ridesharing, core ridesharing losses improving, ongoing leverage in insurance costs, and the "high-growth, high-margin" revenue opportunities in Lyft Business, Anmuth tells investors in a research note. Further and importantly, on its earnings call last night, Uber (UBER) echoed Lyft's comments on the more favorable operating environment in the U.S., adds the analyst. He keeps an Overweight rating on Lyft with an $86 price target, suggesting 50% potential upside. The stock closed yesterday down $1.43 to $54.83.
05/31/19
WEDB
05/31/19
NO CHANGE
Target $65
WEDB
Outperform
Uber's Q1 'an important step,' says Wedbush
Wedbush analyst Ygal Arounian reiterated an Outperform rating and $65 price target on Uber following the comany's Q1 results, saying the report was an "important step" for the company as investors needed a bridge between near-term headwinds and the long-term vision working. Additionally, Arounian says he feels that the results addressed many concerns investors had been seeking clarity on, despite not giving revenue or EBITDA guidance for the full year.
IOVA Iovance Biotherapeutics
$17.83

0.7 (4.09%)

05/16/19
BARD
05/16/19
NO CHANGE
Target $34
BARD
Outperform
Iovance Biotherapeutics price target raised to $34 from $29 at Baird
Baird analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $34 from $29 and maintained an Outperform rating, citing increased tumor-infiltrading lymphocyte technology conviction on ASCO abstracts in cervical cancer and metastatic melanoma. The abstracts for Phase 2 data for TIL technology increases his conviction in Iova's TILs, particularly in cervical cancer, the analyst says in a research note.
05/16/19
JEFF
05/16/19
NO CHANGE
Target $29
JEFF
Buy
Jefferies calls Iovance 'big winner' at ASCO, sees up to 40% share rally
Jefferies analyst Biren Amin calls the data reported by Iovance Biotherapeutics (IOVA) the "big winner" for the American Society of Clinical Oncology annual meeting. The ASCO update suggests Iovance's tumor infiltrating lymphocytes therapy could open the door for cell therapy in the "lucrative" solid-tumor market, Amin tells investors in a research note. He points out the company reported that no new patients have progressed in the melanoma trial and offered first evidence of clinically meaningful durability for TIL therapy. Also, its cervical data that reported a 44% overall response rate is three-times greater than reported with Merck's (MRK) Keytruda in a similar patient population, contends Amin. He believes last night's update could drive a 30%-40% rally in shares of Iovance. The analyst keeps a Buy rating on the name with a $29 price target. Iovance in premarket trading is up 26%, or $2.97, to $14.20.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $20
PIPR
Overweight
Iovance Biotherapeutics well positioned in T-cell therapy, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $20 price target on Iovance Biotherapeutics after its Q1 results also disclosed that 3 of its abstracts submitted to ASCO have been accepted. The analyst believes that the company's lifileucel in melanoma update has a "clear opportunity to improve", whiles its LN-145 in cervical cancer data set could be supportive of an accelerated development path. Catanzaro sees Iovance Biotherapeutics as a "best-positioned T-cell therapy" stock, with $440M in cash on hand being sufficient to fund its operations into 2022.
05/23/19
WELS
05/23/19
NO CHANGE
Target $32
WELS
Outperform
Iovance Biotherapeutics price target raised to $32 from $23 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics to $32 from $23 following FDA breakthrough therapy designation for its TIL cell therapy LN-145 in cervical cancer. With ongoing pivotal development in melanoma, the analyst sees a second potential accelerated path to market with breakthrough therapy designation in cervical cancer and sees upside potential to further regulatory update on LN145. Birchenough reiterates an Outperform rating on the shares.
BIG Big Lots
$26.01

-0.42 (-1.59%)

05/24/19
05/24/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Avon Products (AVP) downgraded to Neutral from Buy at DA Davidson. 2. SQM (SQM) downgraded to Market Perform from Outperform at BMO Capital with analyst Joel Jackson saying a lithium rebound or a bottoming in sentiment may take longer and that the company's earnings trajectory no longer warrants a bullish outlook. 3. Lennox (LII) downgraded to Sell from Neutral at UBS with analyst Damian Karas saying the company is trading at a "peak multiple on peak growth." 4. Weibo (WB) downgraded to Reduce from Hold at HSBC. 5. Big Lots (BIG) downgraded to Neutral from Overweight at Piper Jaffray with analyst Peter Keith saying the downgrade is based on risk to first half of 2019 estimates as well as ongoing tariff concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/19
02/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Booking Holdings (BKNG) downgraded to Neutral from Overweight at Atlantic Equities and Piper Jaffray, as well as to Perform from Outperform at Oppenheimer. 2. Box (BOX) downgraded to Sector Weight from Overweight at KeyBanc and to Neutral from Buy at Rosenblatt. 3. HP Inc. (HPQ) double downgraded to Underperform from Buy at BofA/Merrill with analyst Wamsi Mohan citing the company's Q1 report last night. 4. PSEG (PEG) downgraded to Hold from Buy at Deutsche Bank. 5. Dollar General (DG) and Big Lots (BIG) were downgraded to Hold from Buy at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/19
03/19/19
NO CHANGE
Target $44

Overweight
Piper calls Big Lots 'intriguing value/GARP idea' for 2019
After meeting with management, Piper Jaffray analyst Peter Keith highlights Big Lots as an "intriguing value/GARP idea" for 2019. A value idea must be cheap but also have some interesting developments, and Big Lots has several, Keith tells investors in a research note. Some of these, according to the analyst, are remodel benefits building to a 1.5%-2% comp lift, good visibility on gross margin expansion, a $100M cost take-out initiative, and new merchandising initiatives. Keith sees a "healthy" risk/reward on Big Lots shares and reiterates an Overweight rating on the name with a $44 price target.
05/24/19
PIPR
05/24/19
DOWNGRADE
Target $31
PIPR
Neutral
Big Lots downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Peter Keith downgraded Big Lots to Neutral from Overweight and lowered his price target for the shares to $31 from $44. The analyst says the downgrade is based on risk to first half of 2019 estimates as well as ongoing tariff concerns. The analyst believes Big Lots' Q1 was "in-line at best" and that Q2 "appears to have stepped up markdown activity." On tariffs, Big Lots imports 21% of sales from China with a majority now getting tariffed at 25%, Keith tells investors in a research note.
GCO Genesco
$40.25

-0.49 (-1.20%)

01/09/19
PIVT
01/09/19
DOWNGRADE
PIVT
Hold
Genesco downgraded to Hold from Buy at Pivotal Research
08/30/18
08/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tilly's (TLYS) upgraded to Outperform from Market Perform at William Blair with analyst Sharon Zackfia citing improved comp momentum, easing upcoming comparisons against e-commerce issues in the fourth and first quarters, and increased conviction in the company's potential to grow the unit base from 226 sites today. 2. Arlo Technologies (ARLO) upgraded to Buy from Neutral at Guggenheim with analyst Robert Cihra saying the recent pullback in shares offers a compelling buying opportunity and has a meaningful runway to keep growing. 3. Altra Industrial Motion (AIMC) upgraded to Buy from Neutral at Sidoti and to Overweight from Sector Weight at KeyBanc. 4. Genesco (GCO) upgraded to Buy from Hold at Pivotal Research with analyst Mitch Kummetz saying the stock's risk/reward looks more favorable following the company's "strong" Q2 results and the continuation of favorable back-to-school trends into Q3. 5. HD Supply (HDS) upgraded to Buy from Neutral at Northcoast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
08/30/18
PIVT
08/30/18
UPGRADE
Target $54
PIVT
Buy
Genesco upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Mitch Kummetz upgraded Genesco to Buy and raised his price target for the shares to $54 from $44. The stock's risk/reward looks more favorable following the company's "strong" Q2 results and the continuation of favorable back-to-school trends into Q3, Kummetz tells investors in a research note. The analyst points out that Genesco shares haven't run up as much as some of its peers that have already reported "strong" results.
01/09/19
01/09/19
DOWNGRADE
Target $52

Hold
Genesco downgraded to Hold on valuation 'disconnect' at Pivotal Research
As previously reported, Pivotal Research analyst Mitchel Kummetz downgraded Genesco to Hold from Buy as he senses a disconnect between the company's fundamentals and valuation. He believes performance has deteriorated since Genesco reported its Q3 in early December, as he thinks that the boot category "rolled over" in December, but notes that the stock has appreciated 15% over that time. The stock is now trading at a 13% premium to the group, which "seems a little rich," added Kummetz, who keeps a $52 price target on Genesco shares.
WSM Williams-Sonoma
$51.69

0.53 (1.04%)

03/21/19
RBCM
03/21/19
NO CHANGE
Target $60
RBCM
Sector Perform
Williams-Sonoma price target raised to $60 from $54 at RBC Capital
RBC Capital analyst Scot Ciccarelli raised his price target on Williams-Sonoma to $60 after its "solid" Q4 earnings beat that was "heavily" driven by its favorable tax rate. The analyst is also keeping his Sector Perform rating on the shares, stating that in spite of the latest results and modest valuation, he remains concerned with the company's longer-term margin profile as "competitive pricing and free shipping pressures" will likely chip away at margins over time.
03/20/19
EVER
03/20/19
INITIATION
Target $60
EVER
In Line
Williams-Sonoma initiated with an In Line at Evercore ISI
Evercore ISI analyst Oliver Wintermantel started Williams-Sonoma with an In Line rating and $60 base case price target, stating that the company has made very good progress in transforming into a true multichannel retailer. However, the current multiple assumes further profitability declines, as does his model.
03/21/19
MSCO
03/21/19
NO CHANGE
Target $49
MSCO
Underweight
Williams-Sonoma 2019 guidance 'seemingly optimistic,' says Morgan Stanley
Morgan Stanley analyst Simeon Gutman called Williams-Sonoma's Q4 earnings beat "low quality," noting that it was driven by a reversal of one-time charges despite comparable store sales and gross margins that missed expectations. He also thinks the company offered "seemingly optimistic" 2019 guidance, as he believes it will be difficult for Williams-Sonoma to generate 2-5% comp growth and flat EBIT margins in 2019 given that he expects same-store growth at the Pottery Barn and its flagship brand to decelerate and serve as a drag on overall top-line growth. Gutman keeps an Underweight rating and $49 price target on the stock.
05/10/19
BREN
05/10/19
INITIATION
Target $61
BREN
Hold
Williams-Sonoma initiated with a Hold at Berenberg
Berenberg analyst Sumit Sharma started Williams-Sonoma with a Hold rating and $61 price target.
NTNX Nutanix
$32.68

-1.02 (-3.03%)

05/31/19
STFL
05/31/19
NO CHANGE
Target $25
STFL
Hold
Nutanix price target lowered to $25 from $39 at Stifel
Stifel analyst Brad Reback lowered his price target for Nutanix to $25 from $39 saying the company last night reported a "disappointing" quarter and guidance. The company's execution is "uneven" as its subscription transition weighs on results, Reback tells investors in a research note. While shares are "not expensive," Nutanix remains in the "penalty box" and it will take several more quarters to evaluate progress, says the analyst, who keeps a Hold rating on the shares.
05/31/19
PIPR
05/31/19
DOWNGRADE
Target $28
PIPR
Neutral
Piper downgrades Nutanix to Neutral on 'continued execution issues'
Piper Jaffray analyst Andrew Nowinski downgrade Nutanix to Neutral from Overweight and cut his price target for the shares to $28 from $47. The analyst cites the company's "continued execution issues," which he attributes partially to increasing competition, for the downgrade following Nutanix's revenue miss in fiscal Q3. The analyst says that while the valuation at these levels looks attractive, he wants to wait for revenue growth to stabilize before getting more constructive.
05/31/19
BTIG
05/31/19
NO CHANGE
Target $40
BTIG
Buy
Nutanix price target lowered to $40 from $50 at BTIG
BTIG analyst Edward Parker lowered his price target on Nutanix to $40 after its Q3 results, saying the "growing pains" were again visible in the quarter after an "exceptionally poor outlook" provided by the management following Q2. The analyst attributes the underperformance to the headwinds related to the company's accelerated transition to subscription-based revenues and says the results were "disappointing" relative to its prior messaging and channel checks. Parker keeps his Buy rating on the stock however, saying Nutanix has a "strong positioning in a two-horse race" within a hot market.
05/31/19
NEED
05/31/19
NO CHANGE
Target $46
NEED
Buy
Nutanix price target lowered to $46 from $63 at Needham
Needham analyst Jack Andrews lowered his price target on Nutanix to $46 after its "mixed" Q3 results saw a beat on earnings and gross margins and a miss on revenue and billings. The analyst notes that the accelerated shift to term-based licenses "accentuated the compression of billings and revenue" as up-front recognition of revenues was reduced, even though he sees the impact of the transition as "incremental" in terms of the company's "lead generation, go-to-market of new products, and changes to the sales organization." Based on his view of continued robust demand for Nutanix's HCI and cloud-based services, Andrews keeps his Buy rating.
ZUO Zuora
$19.87

-0.46 (-2.26%)

05/31/19
JEFF
05/31/19
NO CHANGE
Target $29
JEFF
Buy
Zuora price target lowered to $29 from $35 at Jefferies
Jefferies analyst John DiFucci lowered his price target for Zuora to $29 from $35 saying the company's fiscal Q1 results were "mixed." The analyst says that while guidance for Q2 was below consensus estimates and reduced for the year, he views this as "prudent." DiFucci continues to believe that Zuora will grow at a rate of at least 25%-30% over the next 5-10 years and he keeps a Buy rating on the shares.
05/31/19
NEED
05/31/19
DOWNGRADE
NEED
Buy
Zuora downgraded to Buy from Strong Buy at Needham
Needham analyst Scott Berg downgraded Zuora to Buy from Strong Buy.
05/31/19
ADAM
05/31/19
NO CHANGE
Target $18
ADAM
Buy
Zuora price target lowered to $18 from $28 at Canaccord
Canaccord analyst Richard Davis lowered his price target on Zuora to $18 from $28 as he believes the firm is executing far below its potential. He noted the shares are sharply lower following its Q1 report and given its price drop, he feels it is not a good time to downgrade the stock. The analyst said if the shares rally back to the high-teens in a few months he would consider a downgrade. Davis maintained his Buy rating on Zuora shares.
05/31/19
NEED
05/31/19
DOWNGRADE
Target $18
NEED
Buy
Zuora downgraded to Buy from Strong Buy at Needham
Needham analyst Scott Berg downgraded Zuora to Buy from Strong Buy and lowered his price target to $18 from $30 after its Q1 results and "materially lower" guidance for FY20 revenue because of its issues around sales execution and challenges with product integration. The analyst believes that the stock could be "dead money" for the next 1-2 quarters, noting that the sales issues are more concerning than the product issues and may require a change in sales leadership. Longer term, Berg maintain a positive view on Zuora as its end-market demand is "still good" and post-earnings selloff valuation is attractive at 4- to 5-times recurring revenues.
GPS Gap
$20.60

-0.23 (-1.10%)

04/03/19
STPT
04/03/19
UPGRADE
STPT
Buy
Gap upgraded to Buy from Hold at Standpoint Research
05/31/19
JPMS
05/31/19
NO CHANGE
Target $17
JPMS
Underweight
Gap price target lowered to $17 from $24 at JPMorgan
JPMorgan analyst Matthew Boss lowered his price target for The Gap to $17 from $24 citing the company's miss in Q1 and guide-down for Q2. The analyst maintains an Underweight rating on the shares.
05/31/19
NOMU
05/31/19
NO CHANGE
Target $22
NOMU
Neutral
Gap price target lowered to $22 from $32 at Nomura Instinet
Nomura Instinet analyst Simeon Siegel lowered his price target for The Gap to $22 from $32 saying the company's Q1 miss, fiscal year guide down and excess inventory weighed on the shares and continued to stress investors' perceptions of the strategic spin off set to occur next year. The analyst keeps a Neutral rating on Gap pending clarity around its stabilization and return to growth.
05/31/19
JEFF
05/31/19
NO CHANGE
Target $40
JEFF
Buy
Gap earnings selloff a buying opportunity, says Jefferies
Jefferies analyst Randal Konik recommends using today's post-earning selloff in shares of The Gap as a buying opportunity. The company's Q1 was "tough," as poor weather hurt traffic trends, Konik tells investors in a research note. While the weather in May hasn't been great, second half of the year comp and margin trends will improve management works to correct assortment and profitability issues, contends the analyst. He believes a bottom is forming in the shares, and continues to view Old Navy as a "crown jewel" that is worth more than the market capitalization of the enterprise today. Konik lowered his price target for Gap to $40 from $50 and keeps a Buy rating on the shares.
PCG PG&E
$17.78

0.64 (3.73%)

02/19/19
02/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Overweight from Equal Weight at Stephens with analyst Will Slabaugh saying McDonald's core U.S. business is accelerating and positioned to show upside to consensus estimates for Q1 and fiscal 2019. 2. PG&E (PCG) upgraded to Buy from Neutral at Citi with analyst Praful Mehta saying recent comments by California Governor Gavin Newsom indicate an "increasingly likelihood of legislative action." 3. PepsiCo (PEP) upgraded to Outperform from Neutral at Macquarie with analyst Caroline Levy saying new CEO Ramon Laguarta "moved decisively" to reset for sustained 4%-6% sales growth by stepping up marketing and capital spending. 4. Freeport McMoRan (FCX) upgraded to Buy from Neutral at Citi while Southern Copper (SCCO) was double upgraded to Buy from Sell. 5. Cosan (CZZ) upgraded to Overweight from Neutral at JPMorgan with analyst Lucas Ferreira saying the shares trade at an "excessive" 40% discount to net asset value, in the upper part of the 30%-40% range where the stock should be trading. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/19
BOFA
04/24/19
NO CHANGE
BOFA
PG&E deal talks report could drive renewed interest, says BofA/Merrill
BofA Merrill Lynch analyst Julien Dumoulin-Smith noted that SparkSpread reported that Berkshire Hathaway Energy (BRK.A) was in talks to acquire bankrupt PG&E (PCG). However, CNBC subsequently reported that Berkshire had no interest, citing direct conversations with Warren Buffett, and a spokesperson also noted the company is not in talks with PG&E, noted the analyst. Still, he thinks headlines regarding the Berkshire interest could help drive renewed interest in PG&E from other large-cap entities, adding that "for all of the same reasons why we see credibility to a potential Berkshire bid, much of the same applies to any other large buyer." Dumoulin-Smith keeps No Rating on PG&E shares given ongoing Chapter 11 proceedings.
04/15/19
SBSH
04/15/19
NO CHANGE
SBSH
Citi reiterates Buy ratings on PG&E, Edison after strike team report
Governor Newsom's press conference and the strike team report unveiled on Friday gives confidence that California will "get something constructive accomplished by July," Citi analyst Praful Mehta tells investors in a research note. The Governor highlighted that a solution requires participation from everybody including investors, insurers, attorneys and tax payers, adds the analyst. He finds this statement "extremely important" and reiterates Buy ratings on both PG&E (PFE) and Edison International (EIX).
02/26/19
ARGS
02/26/19
UPGRADE
ARGS
Hold
PG&E upgraded to Hold from Sell at Argus

TODAY'S FREE FLY STORIES

ARCE

Arco Platform

$43.38

-2.35 (-5.14%)

05:41
06/25/19
06/25
05:41
06/25/19
05:41
Initiation
Arco Platform initiated  »

Arco Platform initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$129.65

-1.32 (-1.01%)

, EOLS

Evolus

$13.69

0.13 (0.96%)

05:40
06/25/19
06/25
05:40
06/25/19
05:40
Recommendations
Allergan, Evolus analyst commentary  »

Allergan price target…

AGN

Allergan

$129.65

-1.32 (-1.01%)

EOLS

Evolus

$13.69

0.13 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

QSR

Restaurant Brands

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Restaurant Brands initiated  »

Restaurant Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$83.65

-0.16 (-0.19%)

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Starbucks initiated  »

Starbucks initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

  • 09

    Jul

DPZ

Domino's Pizza

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Domino's Pizza initiated  »

Domino's Pizza…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 13

    Nov

SHAK

Shake Shack

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Shake Shack initiated  »

Shake Shack initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 09

    Jul

  • 14

    Aug

MCD

McDonald's

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
McDonald's initiated  »

McDonald's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CMG

Chipotle

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Chipotle initiated  »

Chipotle initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

PZZA

Papa John's

$44.13

-0.25 (-0.56%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Papa John's initiated  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

WEN

Wendy's

$19.15

-0.22 (-1.14%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Wendy's initiated  »

Wendy's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 14

    Aug

  • 13

    Nov

YUM

Yum! Brands

$110.62

0.35 (0.32%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Yum! Brands initiated  »

Yum! Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNKN

Dunkin' Brands

$81.01

1.47 (1.85%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Dunkin' Brands initiated  »

Dunkin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

JACK

Jack in the Box

$82.83

-2.33 (-2.74%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Jack in the Box initiated  »

Jack in the Box initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 08

    Aug

PYX

Pyxus

$13.42

-1.1 (-7.58%)

05:36
06/25/19
06/25
05:36
06/25/19
05:36
Initiation
Pyxus initiated  »

Pyxus initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$137.80

0.86 (0.63%)

, AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

05:30
06/25/19
06/25
05:30
06/25/19
05:30
Recommendations
Microsoft, Amazon.com analyst commentary  »

Microsoft Azure likely…

MSFT

Microsoft

$137.80

0.86 (0.63%)

AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

XONE

ExOne

$7.38

-0.21 (-2.77%)

, SIEGY

Siemens

$0.00

(0.00%)

05:28
06/25/19
06/25
05:28
06/25/19
05:28
Hot Stocks
ExOne announces partnership with Siemens »

ExOne (XONE) announced a…

XONE

ExOne

$7.38

-0.21 (-2.77%)

SIEGY

Siemens

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPTN

SpartanNash

$10.87

-0.05 (-0.46%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Initiation
SpartanNash initiated  »

SpartanNash initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$9.51

-0.405 (-4.08%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Hot Stocks
Almirall exercises option with Dermira to license rights to lebrikizumab in EU »

Almirall and Dermira…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGHF

Telenet

$0.00

(0.00%)

05:15
06/25/19
06/25
05:15
06/25/19
05:15
Downgrade
Telenet rating change  »

Telenet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DK

Delek US

$39.13

-0.635 (-1.60%)

05:14
06/25/19
06/25
05:14
06/25/19
05:14
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.43

1.44 (14.41%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Downgrade
Caesars rating change  »

Caesars downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

GRUB

GrubHub

$72.05

0.91 (1.28%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
GrubHub rating change  »

GrubHub upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 09

    Jul

SITE

SiteOne Landscape

$66.97

-0.25 (-0.37%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
SiteOne Landscape rating change  »

SiteOne Landscape…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Hot Stocks
Amazon announces 48 hour Prime Day July 15 & 16 »

Amazon said, "This…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 10

    Jul

BHF

Brighthouse Financial

$38.10

-0.01 (-0.03%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Downgrade
Brighthouse Financial rating change  »

Brighthouse Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.